Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Relative survival

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    590 result(s) found for: Relative survival. Displaying page 1 of 30.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2020-000346-33 Sponsor Protocol Number: D361BC00001 Start Date*: 2020-07-20
    Sponsor Name:AstraZeneca AB
    Full Title: Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone as Treatment for Patients with DeNovo Metastatic Ho...
    Medical condition: Metastatic Hormone-Sensitive Prostate Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Trial now transitioned) BG (Trial now transitioned) CZ (Trial now transitioned) GB (GB - no longer in EU/EEA) SK (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001555-40 Sponsor Protocol Number: D910GC00001 Start Date*: 2020-11-13
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Patients with Resectable Gastr...
    Medical condition: Histologically documented gastric or gastroesophageal junction adenocarcinoma with resectable disease (Stage II or higher per AJCC 8th edition).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004394-40 Sponsor Protocol Number: TRIPLETE Start Date*: 2017-06-22
    Sponsor Name:Fondazione GONO
    Full Title: Randomized phase III study of triplet mFOLFOXIRI plus PANITUMUMAB versus mFOLFOX6 plus PANITUMUMAB as initial therapy for unresectable RAS and BRAF wild-type metastatic colorectal cancer patients
    Medical condition: Metastatic Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-003635-31 Sponsor Protocol Number: IM103-008 Start Date*: 2005-12-12
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial (BENEFIT). Revised Protocol 05 incorporating Protocol Amendments 13 (dated 10-Feb-2011)
    Medical condition: TRANSPLANTATION,NOS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) BE (Completed) GB (Completed) CZ (Completed) IT (Completed) DE (Completed) ES (Completed) SE (Completed) HU (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001022-22 Sponsor Protocol Number: COV-2-STs Start Date*: 2021-05-14
    Sponsor Name:Γενικό Νοσοκομείο Θεσσαλονίκης "Γεώργιος Παπανικολάου"
    Full Title: Generation of SARS-CoV-2-specific T lymphocytes from recovered donors and administration to high-risk COVID-19 patients
    Medical condition: COVID-19 high-risk patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000546-17 Sponsor Protocol Number: D8534C00001 Start Date*: 2021-07-28
    Sponsor Name:AstraZeneca AB
    Full Title: SERENA-6: A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor...
    Medical condition: Estrogen Receptor-Positive, HER-2 negative Advanced Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) BG (Trial now transitioned) PT (Trial now transitioned) AT (Trial now transitioned) SK (Trial now transitioned) NO (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000977-35 Sponsor Protocol Number: AtezoTRIBE Start Date*: 2018-09-13
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST
    Full Title: Randomized phase II study of FOLFOXIRI plus BEVACIZUMAB plus ATEZOLIZUMAB versus FOLFOXIRI plus BEVACIZUMAB as first-line treatment of unresectable metastatic colorectal cancer patients
    Medical condition: Metastatic Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002429-12 Sponsor Protocol Number: UC_0160/1613 Start Date*: 2018-01-31
    Sponsor Name:UNICANCER
    Full Title: PERSONALIZED TREATMENT OF METASTATIC CASTRATE-RESISTANT PROSTATE CANCER PATIENTS ACCORDING TO CIRCULATING TUMOR CELLS KINETIC DURING CHEMOTHERAPY
    Medical condition: Metastatic castrate-resistant prostate cancer requiring initiation of chemotherapy
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-004326-19 Sponsor Protocol Number: 69HCL19_0029 Start Date*: 2020-01-27
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Pragmatic management of progressive disease in idiopathic pulmonary fibrosis: a randomized trial
    Medical condition: Idiopathic pulmonary fibrosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-002974-48 Sponsor Protocol Number: IM103-027 Start Date*: 2005-11-17
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - EXTended Criteria Donors (BENEFIT-EXT). Revised Protocol Number 03 incorporating Administrative Lett...
    Medical condition: TRANSPLANTATION, NOS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) AT (Completed) BE (Completed) SE (Completed) DE (Completed) CZ (Completed) IT (Completed) ES (Completed) PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004436-19 Sponsor Protocol Number: Tribe-2 Start Date*: 2014-12-22
    Sponsor Name:G.O.N.O.
    Full Title: First-line FOLFOXIRI plus bevacizumab followed by reintroduction of FOLFOXIRI plus bevacizumab at progression versus FOLFOX plus bevacizumab followed by FOLFIRI plus bevacizumab at progression in f...
    Medical condition: METASTATIC COLORECTAL CANCER
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003433-37 Sponsor Protocol Number: 213410 Start Date*: 2021-03-10
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A RANDOMIZED, OPEN-LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARLIMAB + DOCETAXEL TO DOSTARLIMAB + DOCETAXEL TO DOCETAXEL ALONE IN PARTICIPANTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WHO HAV...
    Medical condition: Nonsmall Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) SE (Trial now transitioned) NL (Trial now transitioned) RO (Trial now transitioned) GR (Trial now transitioned) BE (Trial now transitioned) FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001787-10 Sponsor Protocol Number: IG1407 Start Date*: 2019-01-12
    Sponsor Name:Instituto Grifols S.A.
    Full Title: Effects of Plasma Exchange with Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects with "Acute-On-Chronic Liver Failure" (ACLF) at High Risk of Hospital Mortality
    Medical condition: Subjects with cirrhosis with ACLF-1b, ACLF-2, or ACLF-3a detected either at admission or during hospitalization
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004871 10064704 Decompensated cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) PT (Completed) DE (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) DK (Completed) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001152-42 Sponsor Protocol Number: ShaperonC002 Start Date*: 2022-09-05
    Sponsor Name:Shaperon, Inc.
    Full Title: A Randomized, Double-blinded, Placebo-controlled, Parallel-treatment Group, Adaptive Design, Multi-center, Phase 2b/3 Trial to Evaluate Efficacy and Safety of NuSepin® Intravenous Infusion in COVID...
    Medical condition: COVID-19 Pneumonia Patients
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) HR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-006312-31 Sponsor Protocol Number: D3610C00002 Start Date*: 2012-07-20
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase I/II, Multicentre, Study Comprising a Safety Run-In of AZD5363 when Combined with Paclitaxel in Patients with Advanced or Metastatic Breast Cancer; Followed by a Randomised Expansion of AZD...
    Medical condition: Advanced or metastatic breast cancer, ER+ve advanced or metastatic breast cancer, safety and tolerability, pharmacokinetics, pharmacodynamics, tumour response, PIK3CA
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2007-000383-24 Sponsor Protocol Number: D8480C00055 Start Date*: 2008-02-20
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTIN™, AZD2171] Monotherapy and the Combination of Cediranib...
    Medical condition: Glioblastoma - a primary brain tumour
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) NL (Completed) BE (Completed) CZ (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-000634-33 Sponsor Protocol Number: D967SC00001 Start Date*: 2021-11-02
    Sponsor Name:ASTRAZENECA AB
    Full Title: An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harb...
    Medical condition: Unresectable, locally advanced, or metastatic Non-Small Cell Lung Cancer with HER2 exon 19 or 20 mutations
    Disease: Version SOC Term Classification Code Term Level
    24.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10084787 HER2 mutant non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-004606-21 Sponsor Protocol Number: D926NC00001 Start Date*: 2022-10-11
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-...
    Medical condition: NSCLC
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) GR (Trial now transitioned) SE (Trial now transitioned) BG (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001707-31 Sponsor Protocol Number: Protocolversion1.0 Start Date*: 2015-07-10
    Sponsor Name:Hull & East Yorkshire Hospitals NHS Trust
    Full Title: The SCaIPEL study: Survival and Quality of Life of Cancer Patients with Incidental Pulmonary Embolism Treated with LMWH
    Medical condition: Incidental Pulmonary Embolism in Cancer Patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001501-24 Sponsor Protocol Number: AVETRIC Start Date*: 2020-02-13
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST
    Full Title: PHASE II STUDY OF AVELUMAB AND CETUXIMAB AND MODIFIED FOLFOXIRI AS INITIAL THERAPY FOR RAS WILD-TYPE UNRESECTABLE METASTATIC COLORECTAL CANCER PATIENTS
    Medical condition: Metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 21 13:37:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA